Letters to the Editor
Early Access
Successful treatment of refractory generalized granuloma annulare with abrocitinib
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 23 January 2026
364
Views
184
Downloads
Authors
Dear Editor,
Granuloma annulare is a chronic inflammatory skin disorder characterized by annular dermal papules and plaques. While localized forms often resolve spontaneously, generalized granuloma annulare tends to persist and frequently proves resistant to conventional therapies. The pathogenesis of the disease remains unclear, but increasing evidence suggests a dysregulated immune response involving T cells, macrophages, and cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and interferon-gamma (IFN-γ). [...]
Downloads
Download data is not yet available.
Citations
1. Wang J, Khachemoune A. Granuloma Annulare: A Focused Review of Therapeutic Options. Am J Clin Dermatol 2018;19:333-44. DOI: https://doi.org/10.1007/s40257-017-0334-5
2. Albert M, Maruani A, Leducq S. Clinical Manifestations and Management of Pediatric Granuloma Annulare: A Systematic Review. J Pediatr 2023;257:113392. DOI: https://doi.org/10.1016/j.jpeds.2023.03.006
3. Schmieder SJ, Harper CD, Schmieder GJ. Granuloma Annulare. 2023 Jun 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. DOI: https://doi.org/10.1007/978-3-031-20343-5
4. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol 2017;76:736-44. DOI: https://doi.org/10.1016/j.jaad.2016.12.005
5. Tancredi V, Buononato D, Caccavale S, et al. New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis. Int J Mol Sci 2023;25:362. DOI: https://doi.org/10.3390/ijms25010362
6. Piette EW, Rosenbach M. Granuloma annulare: Pathogenesis, disease associations and triggers, and therapeutic options. J Am Acad Dermatol 2016;75:467-79. DOI: https://doi.org/10.1016/j.jaad.2015.03.055
7. Michels A, Heiland R, Hammerschmidt S, et al. Successful treatment of recalcitrant generalized granuloma annulare with the JAK inhibitor abrocitinib. J Dtsch Dermatol Ges 2024;22:841-3. DOI: https://doi.org/10.1111/ddg.15426
8. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020;396:255-66. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
How to Cite
1.
Giorgio CM, Balato A, Licata G, Tancredi V, Argenziano G, Di Brizzi EV. Successful treatment of refractory generalized granuloma annulare with abrocitinib. Dermatol Reports [Internet]. 2026 Jan. 23 [cited 2026 May 24];. Available from: https://journals.pagepress.net/dr/article/view/10296
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
